Biocon Limited has informed the Exchange about Intimation of the approval of the audited consolidated financial statements for the financial year March 31, 2025
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon Limited's Board of Directors, at its meeting on May 8, 2025, approved the audited consolidated financial statements for FY ended March 31, 2025, which remain subject to shareholder approval at the AGM on August 8, 2025. The auditor, BSR & Co. LLP, issued an unqualified (clean) opinion on the consolidated financials. However, the auditor flagged 'Going Concern' as a Key Audit Matter, citing put option obligations owed to financial investors from the Viatris biosimilar business acquisition, along with certain long-term borrowings carrying drag-along rights. The company is relying on refinancing, re-negotiating exit terms, and raising fresh funds to manage these obligations. Goodwill of Rs. 167,593 million and intangible assets of Rs. 57,590 million tied to the biosimilar acquisition remain significant and are subject to annual impairment testing. CARO flagged certain unfavorable remarks on Biocon and a few subsidiaries.
For shareholders, the clean audit opinion is positive, but the going concern flag tied to investor exit obligations is a yellow signal — it highlights material near-term liquidity and refinancing risk. Investors should watch the AGM outcome and any updates on renegotiation with financial investors, as these obligations could pressure cash flows or require fresh equity raises.